Roche’s Gazyva/Gazyvaro Shows Superiority To Standard Therapy In Phase III Lupus Nephritis Study
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Roche (RHHBY) announced that the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in patients with active lupus nephritis has yielded positive topline results.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-139800984-5d6b247e19d94a4c86617ccf37b94a89.jpg "Are Credit Card Rewards Considered Taxable Income?")
:max_bytes(150000):strip_icc():format(jpeg)/INV_Gold_Bars_GettyImages-1852385549-f965387598f74025bc1eb57e9d49d05b.jpg "Got an Extra 0? Here’s How Much You Could Make in 20 Years Investing in Gold")
